Accelerate Diagnostics

Accelerate Diagnostics, Inc. is an in vitro diagnostics company, which engages in the provision of solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. It also focuses on developing and commercializing innovative instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The firm's products include Accelerate Pheno and Accelerate PhenoTest. The company was founded in 1982 and is headquartered in Tucson, AZ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Accelerate Diagnostics reports Q1 losses but shows growth potential

Accelerate Diagnostics showcased growth potential with customer acquisitions, Wave program progress, and strategic partnerships, despite facing cost management challenges.
The company's focus on innovation, customer engagement, and operational efficiency positions it for market expansion and technology advancement in the diagnostics sector.
Addressing expense control, successful commercialization of new programs, and sustaining growth momentum are key focus areas for Accelerate Diagnostics to drive profitability.

Accelerate Diagnostics reports Q3 milestones amidst financial challenges

Accelerate Diagnostics demonstrated financial performance with notable milestones achieved in Q3 2024.
While facing challenges in managing cash burn and addressing analyst inquiries, the company showcased strengths in commercial progress and innovation.
Opportunities for growth and market leadership exist through leveraging recent FDA clearances and expanding into new markets.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 21.88% and 2%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Accelerate Diagnostics (AXDX) Reports Q1 Loss, Tops Revenue Estimates

TUCSON, Ariz. , May 16, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the first quarter for the period ended March 31, 2022.

Accelerate Diagnostics Reports First Quarter 2022 Financial Results

Commercialization of Accelerate Arc system, which includes the Accelerate Arc Module and BC kit, unlocks the path to automated, rapid microbial ID for positive blood cultures across the large installed base of MALDI system users. The Accelerate Arc system can cut hours of wait time, eliminate laborious hands-on sample prep, and offer significant cost savings for healthcare facilities compared to current methods.

Accelerate Diagnostics announces commercialization of its Accelerate Arc™ system having completed IVD registration with FDA

TUCSON , April 29, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Monday, May 16, 2022, at 4:30 p.m. Eastern Time to review 2022 first quarter results.

Accelerate Diagnostics scheduled call to review 2022 first quarter results.

New data shows the Accelerate Arc System enables automated and rapid sample preparation that yields robust reportability and accurate microbial identification for positive blood cultures using MALDI when compared to conventional MALDI methods TUCSON, Ariz. , April 25, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) an in-vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis, today announced the release of new data on the Accelerate Arc Module and BC kit at the 32nd European Congress for Clinical Microbiology and Infectious Diseases (ECCMID) located in Lisbon, Portugal 23-26 April 2022.

Accelerate Diagnostics Presents New Data at ECCMID 2022 Demonstrating Rapid and Accurate Results Using Automated Accelerate Arc™ Module and BC Kit

The Accelerate Arc System cuts hours of wait time and numerous manual steps to deliver Identification (ID) results Unlocks rapid microbial ID from positive blood cultures for the large installed base of MALDI system users TUCSON, Ariz. , March 28, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) an in-vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis, today announced the launch of the Accelerate Arc system, comprised of the Arc Module and BC Kit, an automated path to rapid and accurate microbial identification for positive blood cultures.

Accelerate Diagnostics Announces Launch Of Accelerate Arc™ Module and BC Kit

Accelerate Diagnostics' (AXDX) CEO Jack Phillips on Q4 2021 Results - Earnings Call Transcript

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 23.33% and 3.13%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Accelerate Diagnostics (AXDX) Reports Q4 Loss, Tops Revenue Estimates

TUCSON, Ariz., March 8, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the fourth quarter and full year ended December 31, 2021.

Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2021 Financial Results

TUCSON, Ariz., Feb. 24, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Wednesday, March 8, 2022, at 4:30 p.m.

Accelerate Diagnostics scheduled call to review 2021 fourth quarter and full year results

Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Accelerate Diagnostics (AXDX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

TUCSON, Ariz., Feb. 2, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that the company is scheduled to present virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 16, 2022, at 10:00 a.m.

Accelerate Diagnostics to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 16, 2022, at 10:00 a.m. Eastern Time

Pixelworks

Epizyme

The Euro surged to $1.13 against the US dollar this morning after recent data showed the Eurozone inflation increased to a new record high of 5.1% in January. Investors, meanwhile, focused on some notable insider trades.

Insiders Buying Pixelworks And 4 Other Penny Stocks

TUCSON, Ariz., Jan. 13, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced preliminary financial results for the quarter and year ending December 31, 2021.

Accelerate Diagnostics Announces Preliminary Fourth Quarter & Full-Year 2021 Financial Results

TUCSON, Ariz., Jan. 12, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) announced today that it was honored as a recipient of China's Suzhou Industrial Park's (SIP) 15th Science and Technology Leaders Innovation Award for the Company's Accelerate Pheno® System.

Accelerate Diagnostics Wins Suzhou Innovation Award to Support Continued China Commercialization Efforts

TUCSON, Ariz., Dec. 29, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) announced today that the company is scheduled to present at the 40th Annual J.

Accelerate Diagnostics to Participate Virtually in 40th Annual J. P. Morgan Healthcare Conference on January 13, 2022

Amneal Pharmaceuticals

Venus Concept

XpresSpa Group

Insiders are buying these penny stocks during "tax loss season" The post Penny Stocks To Buy Now According To Insiders In December 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Buy Now According To Insiders In December 2021

TUCSON, Ariz., Nov. 22, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) today announced the publication of its Improving Outcomes and Antibiotic Stewardship (IOAS) Study in the journal Clinical Infectious Diseases.

New Accelerate Pheno® System Multi-Center Study Published in Clinical Infectious Diseases

Accelerate Diagnostics, Inc. (AXDX) CEO Jack Phillips on Q3 2021 Results - Earnings Call Transcript

TUCSON, Ariz., Nov. 9, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced preliminary financial results for the third quarter for the period ended September 30, 2021, which remain subject to quarter end closing adjustments.

Accelerate Diagnostics Reports Third Quarter 2021 Financial Results

Earnings Preview: Accelerate Diagnostics (AXDX) Q3 Earnings Expected to Decline

TUCSON, Ariz., Oct. 19, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. announced today that management will host a conference call on Tuesday, November 9, 2021, at 4:30 p.m.

Accelerate Diagnostics Schedules Call to Review 3rd Quarter 2021 Results

TUCSON, Ariz., Sept. 23, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced that it has entered into separate, privately negotiated exchange agreements with certain holders of its 2.50% Convertible Senior Notes due 2023 (the "Notes").

Accelerate Diagnostics Announces Agreements to Exchange Approximately $51 Million in Principal Amount of Its 2.50% Convertible Senior Notes due 2023 for Common Stock

Accelerate Diagnostics, Inc. (AXDX) CEO Jack Phillips on Q2 2021 Results - Earnings Call Transcript

TUCSON, Ariz., Aug. 5, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the second quarter for the period ended June 30, 2021.

News for Accelerate Diagnostics Stock (AXDX)